PepGen Board of Directors Announces Dr. Ashton’s Retirement
PepGen Inc. (Nasdaq: PEPG), a pioneering biotechnology company focused on advancing next-generation oligonucleotide therapies, has announced that Dr. Christopher Ashton will retire from its Board of Directors. His retirement will become effective at the end of September 2024. Dr. Ashton has been a key member of the team since December 2019, contributing significantly on both the audit and compensation committees.
Expressing Gratitude for Dr. Ashton’s Contributions
Laurie Keating, JD, the Chair of PepGen’s Board, expressed deep appreciation for Dr. Ashton’s service. “On behalf of the Board of Directors, I want to sincerely thank Chris for nearly five years of dedicated work. His wisdom and humility have had a lasting impact. As our longest-serving Director, his dual contributions as a scientist and leader have greatly influenced the company’s success. We wish him nothing but the best as he moves forward,” Keating remarked.
Dr. Ashton Reflects Positively on PepGen’s Progress
In reflecting on his time with PepGen, Dr. Ashton stated, “It's been incredibly fulfilling to help transform PepGen from its early days into a clinical-stage biotechnology company. With two investigational therapies currently in clinical trials targeting serious neuromuscular and neurological disorders, I see a bright future ahead. I remain hopeful that these candidates might become best-in-class treatments that could greatly benefit patients.”
What’s Next for Dr. Ashton?
Dr. Ashton shared that his decision to retire stems from a desire to focus on advising pre-IPO companies. He clarified that there are no disputes or disagreements with PepGen or its Board about company policies or operations. After his departure, the Board of Directors will reduce its membership from seven to six members.
About PepGen
PepGen is leading the way in biotechnology, specializing in the development of oligonucleotide therapies for severe neuromuscular and neurological diseases. The company’s Enhanced Delivery Oligonucleotide (EDO) platform is built on over a decade of research and aims to utilize cell-penetrating peptides. This approach enhances the delivery and effectiveness of oligonucleotide therapeutics. Through the EDO platform, PepGen intends to build a strong pipeline of therapies that tackle the underlying causes of critical health issues.
Further Contact and Information
For more information, please visit our website. PepGen is eager to stay connected across various platforms, including LinkedIn and X. We invite you to join us as we continue our journey toward developing transformative therapies.
Frequently Asked Questions
Which company is undergoing a leadership transition?
PepGen Inc. is currently experiencing a leadership change with Dr. Christopher Ashton stepping down from the Board of Directors.
When will Dr. Ashton officially retire?
Dr. Ashton’s retirement will take effect at the end of September 2024.
Why is Dr. Ashton leaving the Board?
He plans to focus on advising pre-IPO companies as his new primary objective.
What is the significance of Dr. Ashton’s role on the Board?
Dr. Ashton has played a crucial role in steering PepGen’s growth and strategic decisions over the nearly five years of his service.
What are PepGen's primary areas of focus?
PepGen specializes in advancing groundbreaking therapies for severe neuromuscular and neurological diseases by utilizing innovative oligonucleotide technology.
